Bacterial molecules may prevent inflammatory bowel disease

VBL Therapeutics Discloses Data about VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis

It is a huge advance, says Sarkis Mazmanian of Caltech. This opens up the notion that a very easy and potentially very safe therapy for inflammatory bowel disease could exist. Decades of research have hinted that microbes play a role in immune-related diseases such as obesity, allergy, inflammatory bowel disease and colon cancer. But scientists have had difficulty pinpointing direct links between the bacteria in the gut and the army of immune cells that live there. Some researchers have focused on individual microbial species among the guts teeming hordes to see how they affect the immune system. But Wendy Garretts team at Harvard University decided to look instead for possible immune tamers among the various molecules that many different bacteria make. The team chose to investigate short-chain fatty acids because bacterial species that make large amounts are in short supply in some people with inflammatory bowel disease. To see whether the microbial molecules play a role in quieting the immune system, the researchers added them to mices drinking water. The animals developed elevated levels of inflammation-dousing regulatory T cells in their colons, the team reports July 4 in Science. The cells work like wet blankets, dampening autoimmune flare-ups before they burn out of control. The team also found that those short-chain fatty acids protected the mice from an experimental form of colitis, an immune disease that destroys the colon. Garrett hopes that the acids play the same role in tamping down inflammation in people. try these guys

In the second model, VB-201 inhibited atherosclerosis development in ApoE knockout mice with clear evidence of reduced lesional macrophage staining. Over the past few decades, prevention and treatment of atherosclerosis has been mostly focused on regulation of cholesterol and blood-pressure. Nevertheless, numerous recent studies have emphasized that inflammation plays a significant role in atherosclerosis, and this key vector has not been adequately met thus far. The current findings demonstrate for the first time in vivo inhibition of monocytes migration by an oral phospholipid-based small molecule. VB-201 reduces macrophage accumulation and decreases experimental atherosclerotic lesion development without affecting the cholesterol or triglyceride levels. We are excited to share these mechanistic and pre-clinical results with the cardiovascular and immunology community, said Eyal Breitbart, PhD, VBLs VP for R&D. VBLs intensive research of native anti-inflammatory mechanisms has led us to the development of the Lecinoxoid pipeline of small molecules, which unlike current drugs in the atherosclerosis field, do not affect the lipid profile but rather modulate the inflammatory process in this disease. Due to its MOA, VB-201 may add significant value to atherosclerosis patients on top of statins. VBL Therapeutics has recently announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation, which was measured by PET-CT. We are currently evaluating VB-201 in two Phase 2 clinical trials to treat psoriasis and Inflammatory Bowel Disease after demonstrating proof of efficacy in a recently completed phase 2 study in moderate-to-severe psoriasis patients with cardiovascular risk, said Professor Dror Harats, M.D., chief executive officer of VBL. The pre-clinical findings reported in this manuscript seem to be well translated to humans, as the clinical data we have gathered so far consistently demonstrate the potential of VB-201 as a safe, novel oral therapeutic option for chronic immune-inflammatory diseases. About VB-201 VB-201 is a proprietary, first-in-class, orally-available, specific innate immunity disease modifying medicine in development for the effective treatment of chronic immune-inflammatory diseases. VB-201 offers the potential to deliver long-term control of a spectrum of immune-inflammatory indications with a favorable safety profile. VB-201 has completed Phase 2 study in patients with moderate-to-severe psoriasis and a sub-study in patients with cardiovascular risk which have successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation. Altogether, the product has successfully completed five clinical trials involving more than 400 subjects under U.S. navigate to this web-site